Verity Asset Management Inc. Buys New Stake in Amgen Inc. (NASDAQ:AMGN)

Verity Asset Management Inc. bought a new stake in Amgen Inc. (NASDAQ:AMGN) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,938 shares of the medical research company’s stock, valued at approximately $318,000.

A number of other large investors have also recently modified their holdings of AMGN. Camelot Portfolios LLC acquired a new stake in Amgen during the first quarter worth approximately $1,429,000. Telos Capital Management Inc. lifted its position in Amgen by 1.6% during the first quarter. Telos Capital Management Inc. now owns 14,348 shares of the medical research company’s stock worth $2,354,000 after acquiring an additional 227 shares during the last quarter. Cadence Bank NA lifted its position in Amgen by 6.2% during the first quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock worth $554,000 after acquiring an additional 197 shares during the last quarter. Palladium Partners LLC raised its position in shares of Amgen by 1.9% in the first quarter. Palladium Partners LLC now owns 112,042 shares of the medical research company’s stock valued at $18,382,000 after buying an additional 2,079 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS raised its position in shares of Amgen by 70.6% in the first quarter. Kornitzer Capital Management Inc. KS now owns 38,865 shares of the medical research company’s stock valued at $6,377,000 after buying an additional 16,080 shares in the last quarter. Institutional investors and hedge funds own 78.09% of the company’s stock.

AMGN has been the subject of a number of analyst reports. Oppenheimer Holdings, Inc. set a $189.00 price target on shares of Amgen and gave the company a “buy” rating in a research report on Tuesday, June 13th. Mizuho reiterated a “buy” rating and issued a $195.00 price target on shares of Amgen in a research report on Sunday, July 9th. ValuEngine upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Jefferies Group LLC reiterated a “buy” rating and issued a $195.00 price target on shares of Amgen in a research report on Tuesday, July 11th. Finally, Cann reissued a “buy” rating and issued a $203.00 price objective (up from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $186.14.

COPYRIGHT VIOLATION WARNING: “Verity Asset Management Inc. Buys New Stake in Amgen Inc. (NASDAQ:AMGN)” was reported by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/verity-asset-management-inc-buys-shares-of-1938-amgen-inc-amgn/1605112.html.

Amgen Inc. (AMGN) opened at 185.76 on Friday. Amgen Inc. has a one year low of $133.64 and a one year high of $191.10. The firm has a market cap of $135.54 billion, a price-to-earnings ratio of 16.92 and a beta of 1.35. The stock’s 50 day moving average is $175.99 and its 200 day moving average is $169.31.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. Amgen’s revenue was up 2.1% on a year-over-year basis. During the same period last year, the firm posted $2.84 EPS. On average, analysts predict that Amgen Inc. will post $12.57 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were given a $1.15 dividend. This represents a $4.60 annualized dividend and a dividend yield of 2.48%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s payout ratio is currently 41.93%.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with our FREE daily email newsletter.

 


Latest News

American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22


Leave a Reply

 
© 2006-2017 BBNS.